Core Viewpoint - He Eye Hospital's refractive business is projected to achieve revenue of 135 million yuan in the first half of 2025, reflecting a year-on-year growth of 3.26%, indicating a return to a growth trajectory [1] Group 1: Business Performance - The refractive surgery average selling price (ASP) is on the rise due to an increased proportion of high-value procedures such as femtosecond laser and ICL crystal implantation [1]

Group 1: Strategic Planning and Regional Development - The company focuses on a regional development strategy of "deepening in Liaoning, radiating nationwide, hierarchical layout, and precise expansion," targeting core urban clusters such as Beijing-Tianjin-Hebei, Chengdu-Chongqing, Greater Bay Area, and Yangtze River Delta [2][3] - Liaoning serves as the core base and profit pillar, maintaining stable operations and good cash flow, while expanding into provinces like Beijing, Chongqing, Chengdu, and Hainan [3] - The company is optimizing operations by closing underperforming units to enhance overall efficiency without affecting the national layout [3] Group 2: Business Performance and Financial Metrics - Refractive surgery revenue was 239 million CNY in 2023, projected to decrease to 218 million CNY in 2024, a decline of 9.08%, but expected to recover to 135 million CNY in the first half of 2025, a growth of 3.26% [4][5] - Vision care revenue was 387 million CNY in 2023, expected to drop to 365 million CNY in 2024, a decrease of 5.82%, with a projected revenue of 169 million CNY in the first half of 2025, a decline of 4.95% [4][5] - Cataract surgery revenue is forecasted to be 157 million CNY in 2024, down 23.61% year-on-year, with 7.66 million CNY in the first half of 2025, a decrease of 17.67% [6] Group 3: Business Model and Franchise Development - The company employs a light-asset, replicable franchise model for vision care centers, providing brand authorization, standardized operations, and supply chain support [4] - In the first half of 2025, 23 new vision care stores were signed, bringing the total to 53 [5] Group 4: Competitive Landscape and Market Position - The Liaoning eye care market is evolving with increased competition from public institutions and private chains, necessitating a focus on technical and service excellence [7][8] - The company is enhancing its service offerings through a "365 myopia prevention system" and digital health management initiatives [8] Group 5: International Expansion and Investment - The acquisition of 70.65% of Japan's Medical Pathway is a strategic move to integrate advanced regenerative medical technologies and enhance the company's competitive edge in global markets [8] - The investment aims to leverage collaborations with top universities and enhance research and clinical capabilities [8]